Pear Therapeutics to Participate in 8th Annual SVB Leerink Global Healthcare Conference and Cowen and Company 39th Annual Healthcare Conference
Boston, February 20, 2018 – Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced its participation in the 8thAnnual SVB Leerink Global Healthcare Conference and the Cowen and Company 39thAnnual Healthcare Conference. Details below:
- Christopher D.T. Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will participate in the 8thAnnual SVB Leerink Global Healthcare Conference on February 27 at the Lotte New York Palace.
- Corey McCann, M.D., Ph.D., President and CEO, will present at the Cowen and Company 39thAnnual Healthcare Conference on March 11 at 3:30 p.m. at the Boston Marriott Copley Place.
Pear Therapeutics is a privately held, prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious disease.
About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics. We aim to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurological conditions. Our lead product, reSET®, treats Substance Use Disorder and was the first prescription digital therapeutic to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O™, for the treatment of Opioid Use Disorder, received marketing authorization from the FDA in December 2018. For more information, visit us at www.peartherapeutics.com.
Media and Investors: